Recently, Takeda Pharmaceutical announced its highly selectiveOral TYK2 Inhibitor Zasocitinib(TAK-279) in twoPositive Results Achieved in Key Phase 3 Clinical Trial。Data shows,The study showed that Zasocitinib was significantly superior to placebo at week 16, achieving the co-primary endpoints, with a higher proportion of participants achieving static Physician Global Assessment (sPGA) scores of 0 or 1 compared to placebo.The proportion of participants achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI) from baseline also outperformed placebo, with a significantly higher PASI 75 response rate observed as early as Week 4, which continued to increase through Week 24.These studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100, and sPGA 0 compared to placebo and apremilast, demonstrating the potential of this convenient once-daily oral regimen to achieve complete skin clearance.Based onEfficacy and Safety Profile of ZasocitinibTakeda plans to submit a new drug application for market approval in fiscal year 2026.The drug is expected toWarBristol-Myers SquibbMarket Position of TYK2 Inhibitor Sotyktu.In 2022, BMS announced that the FDA had approved its TYK2 inhibitor Sotyktu (deucravacitinib) for successful market launch, indicated for the treatment of adults with moderate to severe plaque psoriasis. This is the world's first marketed TYK2 inhibitor.In 2024, the global sales of Sotyktu were $246 million., an increase of 45% year-on-year.By the end of 2022, Takeda had$4 billion upfront paymentAcquired from Nimbus TherapeuticsZasocitinib。
Zasocitinib is aMolecules designed by artificial intelligence, byNimbus Therapeutics and AI pharmaceutical company Schrödinger jointly developed a highly selective drug targeting TYK2.
In addition, Takeda is conducting aPhase III Clinical Head-to-Head Study, CompareZasocitinibTreatment with Sotyktu in moderate to severe plaque psoriasis. The trial is expected to be completed by next July.
Not only that, but Takeda also adjusted its pipeline priorities this fall and cutAfter the cell therapy project, Takeda collaborated with an AI drug discovery company.Nabla Bio Reaches Agreement to Refill Its Early-Stage Pipeline.
It is expected that by 2030,The oral psoriasis market is expected to exceed $5 billion, with patients showing a preference for oral medications over injectables.
—END—
